Repligen Corporation · RGEN · FY2026 Q2 · Calendar Q3 2026
Repligen raises guidance as proteins, analytics and APAC drive growth
Repligen's Q2 update strengthened the growth case: proteins, analytics and Asia Pacific supported organic growth, while improving capital-equipment orders and the BioLife acquisition broaden the opportunity. Execution risks remain in filtration, equipment timing and integration.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about RGEN FY2026 Q2
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management raised full-year organic revenue growth guidance to 10–13% and increased adjusted EPS guidance by $0.05. Capital-equipment orders improved sequentially, and Repligen announced a definitive agreement to acquire BioLife.
Guidance delta
Raised: full-year organic revenue growth guidance increased to 10–13%; adjusted EPS guidance increased by $0.05.
Key takeaways
- Q2 revenue reached $204 million, with 13% organic growth.
- Proteins grew 50%, analytics grew 30% and APAC grew 40%, according to management's analysis.
- Capital-equipment orders improved sequentially and backlog is building for 2027.
- BioLife is expected to add a cell-therapy platform and contribute $0.05 of first-year EPS accretion.
Management priorities
- Expand integrated solutions and cross-sell end-to-end offerings.
- Roll out product lifecycle upgrades such as SoloVPE PLUS.
- Integrate BioLife to broaden cell-therapy workflow capabilities.
- Increase sales, R&D and digital investment in the second half of 2026 while expanding in Asia Pacific.
Follow RGEN with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationRepligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand.…
Historical context
All RGEN earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| NVS Novartis AG | FY2026 Q3 · Calendar Q4 2026 | — | +1.2% | Novartis raises profit outlook as priority brands drive Q3 growth |
| RDY Dr. Reddy's Laboratories Limited | FY2027 Q2 · Calendar Q4 2026 | +24.0% | -0.2% | Dr. Reddy’s: margins improve as semaglutide rollout advances |
| DGX Quest Diagnostics Incorporated | FY2026 Q3 · Calendar Q4 2026 | +4.5% | +1.8% | Quest Diagnostics: growth broadens, but PAMA remains a headwind |
| ARGX argenx SE | FY2026 Q3 · Calendar Q4 2026 | — | -1.6% | argenx: VYVGART momentum and a broader late-stage pipeline |
Latest beats and misses
Who reports nextBeat on EPS
- VZFY2026 Q3 · October 26, 2026+3.1% EPS-3.5% move
- CXFY2026 Q3 · October 26, 2026+12.0% EPS-0.1% move
- CDNSFY2026 Q3 · October 26, 2026+2.9% EPS+1.8% move
- BAHFY2027 Q2 · October 23, 2026+18.9% EPS-0.3% move
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
Missed on EPS
- WELLFY2026 Q3 · October 26, 2026-15.8% EPS-5.3% move
- KOFFY2026 Q3 · October 26, 2026-9.0% EPS-1.9% move
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
Get the RGEN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-27T12:03:37.806678+00:00
- FN2 earnings calendar · 2026-09-02T01:23:14.593608+00:00
- Polygon adjusted daily market bars · 2026-10-27T15:30:44.750484+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-27T15:30:44.747618+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-27. For educational purposes only; not investment advice.